The multikinase inhibitor sorafenib is also a Mcl-1 inhibitor, useful in sensitization to ATB-737 treatment, showing a higher apoptosis induction in LN229 and U87 glioma cells. This evidence concerns the gene MCL1 and central nervous system cancer.